Novozymes’ stock consists of two types: A and B shares. Both shares have a nominal value of DKK 2 per share, but an A share carries 10 times as many votes as a B share.

As of December 2016, Novozymes had more than 60,000 shareholders, of whom more than 95% were private shareholders in Denmark. Fourty institutional shareholders, including Novo A/S, owned approximately 50% of the B stock. Investors outside Denmark hold approximately 65% of the B common stock.

As of December 2016 Novo A/S held 26% of the total outstanding common stock and controlled 71% of the votes through its holding of the A common stock and 26,071,400 B shares. The figures related to the number of votes do not take into account treasury shares (own shares) held by Novozymes. Novo A/S is wholly owned by the Novo Nordisk Foundation, and so Novozymes is included in the consolidated financial statements of the Novo Nordisk Foundation. Novo A/S is domiciled in Hellerup, Denmark.